The aim of this work is to do a detailed comparison between multiple sclerosis and Neuromyelitis Optica Spectrum Disorder due to delicate similarities between both diseases and wide rang of management and follow up of the patients
Study Type
OBSERVATIONAL
Enrollment
100
serum Glial Fibrillary Acidic Protein levels
Measurement of serum concentrations of Glial Fibrillary Acidic Protein at baseline using a validated immunoassay (e.g., single-molecule array \[Simoa\] assay). difference in serum Glial Fibrillary Acidic Protein levels between treatment-naïve NMOSD and treatment-naïve MS patientsexpressed in picograms per milliliter (pg/mL).
Time frame: Baseline
Correlation between serum biomarkers (sGFAP and sNfL) and lesion burden on MRI.
Correlation (Pearson or Spearman) between biomarker levels and total T2 lesion count at baseline MRI.
Time frame: Baseline
Correlation between serum biomarkers (sGFAP and sNfL) and Expanded Disability Status Scale (EDSS).
Correlation analysis (Pearson or Spearman depending on distribution) between baseline serum concentrations of sGFAP/sNfL and baseline EDSS scores.
Time frame: Baseline
Association between serum biomarkers and optic nerve involvement (length and presence of LETM).
Correlation between sGFAP/sNfL levels and MRI-measured optic nerve lesion length, including presence of longitudinally extensive transverse myelitis (LETM).
Time frame: Baseline
Diagnostic performance of sGFAP and combined sGFAP + sNfL in differentiating NMOSD from MS.
Assessment of diagnostic accuracy using Area Under the Receiver Operating Characteristic Curve (AUC) for: 1. sGFAP alone 2. Combined biomarker model (sGFAP + sNfL)
Time frame: Baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.